Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company using ribonucleic acid interference (RNAi) to develop medicines that silence genes that cause disease.

https://dicerna.com/

Newton

Diceros Therapeutics

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021.

Dicerna Announces Expiration Of Hart-Scott-Rodino Act Waiting Period For Novo Nordisk Tender Offer To Acquire Dicerna

Dicerna Announces Expiration Of Hart-Scott-Rodino Act Waiting Period For Novo Nordisk Tender Offer To Acquire Dicerna

Company Info

Related People